Immix Biopharma (IMMX) Expected to Announce Earnings on Friday

Immix Biopharma (NASDAQ:IMMX) is expected to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Monday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.09. On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Stock Performance

NASDAQ:IMMX opened at $1.71 on Friday. The company’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $1.86. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $3.23. The stock has a market capitalization of $47.04 million, a P/E ratio of -2.01 and a beta of 0.26.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Monday, February 10th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.